COMMUNIQUÉS West-GlobeNewswire

Medline Inc. announces pricing of upsized secondary offering of Class A common stock
22/05/2026
NORTHFIELD, Ill., May 21, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of its upsized secondary offering of 72,554,594 shares of Medline Inc.’s Class A common stock by [...]
Most Effective Magnesium Pain Cream Researched: Real Magnesium Niacinamide Relief for Peak Health & Nerve Pain Recovery
22/05/2026
How the Magnesium Chloride and Niacinamide Topical Cream with Arnica, Boswellia, Menthol, and Camphor Supports Joint, Nerve, and Muscle Comfort Routines SPEARFISH, SD, May 21, 2026 (GLOBE NEWSWIRE) -- These statements [...]
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
22/05/2026
VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative [...]
FemiCore Claims Evaluated: Investigating the Ingredients for Bladder Support - Femi Core Consumer Complaints Exposed
22/05/2026
FemiCore Ingredients Explained: Mimosa Pudica, Cranberry, Bearberry, Berberine, and 5-Strain Lactobacillus Probiotic Blend for Women's Bladder Support in 2026 Tallmadge, Ohio, May 21, 2026 (GLOBE NEWSWIRE) -- These [...]
TaiMed Biologics Completes Phase 2b Enrollment for TMB-365/380 in HIV Maintenance Therapy Study
22/05/2026
Last Patient In enrolled ahead of schedule; interim analysis anticipated by year-end 2026 to inform plans for the next stage of development TAIPEI, May 21, 2026 (GLOBE NEWSWIRE) -- TaiMed Biologics (TPEX: 4147) today [...]
Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026
22/05/2026
ROCKVILLE, Md. and SUZHOU, China, May 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the [...]
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
22/05/2026
The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue development of BIIB122 [...]
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
22/05/2026
~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK ® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~ ~ Real-World Evidence Shows [...]
Liminatus Pharma Announces Nasdaq Delisting Notification
22/05/2026
FULLERTON, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company received a delisting notice from The Nasdaq Stock Market LLC (“ [...]
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
22/05/2026
The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue development of BIIB122 [...]
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
22/05/2026
HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered [...]
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
21/05/2026
ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients Multiple CR-001 clinical [...]
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
21/05/2026
OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse events OP-3136 shows evidence of anti-tumor activity across multiple solid tumor [...]
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
21/05/2026
At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of [...]
Rgenta Therapeutics Presents Positive Preliminary Data from Ongoing Phase 1a/b Clinical Trial of RGT-61159 in Patients with Adenoid Cystic Carcinoma and Colorectal Cancer at the 2026 ASCO Meeting
21/05/2026
Data for patients treated at or below recommended Phase 2 dose (RP2D) showed 84.6% disease control rate (33/39), including 3 partial responses (2 confirmed, 1 pending confirmation) RGT-61159 was well-tolerated at RP2Ds [...]
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
21/05/2026
Data to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Combined results evaluating AKY-2519 across several B7-H3 expressing tumor types, including metastatic [...]
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
21/05/2026
Updated Phase 2 CRDF-004 data to be presented during ASCO 2026 rapid oral session on June 2, 2026; investor webcast scheduled for June 3, 2026 at 8:30 am ET to review the data SAN DIEGO, Calif., May 21, 2026 (GLOBE [...]
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
21/05/2026
In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was observed with low frequency of high-grade adverse events Activity of the combined regimen across all dose [...]
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
21/05/2026
Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. ( [...]

Pages